<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02784405</url>
  </required_header>
  <id_info>
    <org_study_id>sparta2016</org_study_id>
    <nct_id>NCT02784405</nct_id>
  </id_info>
  <brief_title>Self-apposing Stentys Stents Registry</brief_title>
  <acronym>SPARTA</acronym>
  <official_title>Safety and Effectiveness of the Self-aPposing, bAlloon-delivered, dRug-eluting Stent for the Treatment of the Coronary Artery Disease: A multiCenter Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Città della Salute e della Scienza di Torino</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera Città della Salute e della Scienza di Torino</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Self-apposing, drug-eluting Stentys coronary stents represent a valuable tool for the
      treatment of coronary artery stenosis. Their ability to adapt to widely varying vessel
      calibers and to auto-expand after their release to self-appose to vessel walls is
      particularly useful in the presence of ectasic coronary arteries or significant vessel
      tapering. The investigators planned this study to assess the feasibility, the effectiveness
      and the safety of the implantation of self-apposing, drug-eluting Stentys stents for
      percutaneous coronary intervention.

      Consecutive patients undergoing percutaneous coronary intervention with implantation of a
      self-apposing Stentys stent were enrolled in this multi center registry. Inclusion criteria
      were age ≥ 18 years and ability to provide informed consent. No exclusion criteria were
      defined.

      Primary end-point of the study is the occurrence of MACE (death, myocardial infarction, stent
      thrombosis, unplanned hospitalization for unstable angina, target lesion revascularization).
      Secondary end-points include individual components of MACE, procedural complications
      (periprocedural MI, bleedings, access site complication, failure to cross stent struts with
      guidewire in the treatment of bifurcation, failure to delivery the stent, contrast-induced
      nephropathy), bleedings at follow up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: Choice of the appropriate size of stents in the treatment of coronary artery
      stenosis can often be challenging. Marked tapering of vessels' diameter in their
      proximal-distal development may lead to sub-optimal results. Distal under-expansion of the
      drug-eluting stent (DES) or vessel perforation may occur if a larger DES, best suited for the
      proximal diameter, is chosen. Proximal DES under-sizing with struts malapposition may happen
      if a smaller DES, fitting the distal diameter, is implanted. Moreover, ectasic vessels
      present irregular and varying diameter, which may lead as well to segmental malapposition or
      under-expansion of DES. Self-apposing stents can overcome these limitations thanks to their
      ability to self-expand also after their release in the vessel and to adapt to a wide range of
      vessel diameters. Multiple generation of self-apposing, drug-eluting stents have been
      developed, with progressive amendments pertaining the stent-deployment technique (from
      deployment by covering-sheath retraction to balloon-delivery) and the drug released (from
      paclitaxel to sirolimus). The last generation of the self-apposing stents is represented by
      the sirolimus-eluting, balloon-delivered Xposition S stents. Studies assessing performance of
      this stent are however limited in sample size and length of follow up, and are mainly
      controlled trials. Few data are available regarding the clinical outcomes of the
      self-apposing Stentys stents in a &quot;real-life&quot; setting.

      Aim of this study is to assess the feasibility, the effectiveness and the safety of the
      implantation of self-apposing, drug-eluting Stentys stents for percutaneous coronary
      intervention.

      Study population: Patients undergoing percutaneous coronary intervention with implantation of
      a self-apposing Stentys stent.

      Primary analysis: Longitudinal cohort follow up

      Study end-points:

      Primary efficacy end-point:

        -  Major adverse cardiovascular events (MACE) (a composite end point including death,
           myocardial infarction (MI, excluding periprocedural MI), stent thrombosis, unplanned
           hospitalization for unstable angina, target lesion revascularization (TLR))

      Secondary efficacy end-points:

        -  Individual components of MACE (death, MI, stent thrombosis, unplanned hospitalization,
           TLR)

      Secondary safety end-points:

        -  Procedural complications:

             -  Periprocedural MI

             -  Bleedings

             -  Access site complication

             -  Failure to cross stent struts with guidewire in the treatment of bifurcation

             -  Failure to delivery the stent

             -  Contrast-induced nephropathy

        -  Bleedings at follow up
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Major Adverse Cardiovascular Events (MACE)</measure>
    <time_frame>12 months</time_frame>
    <description>A composite end-point of death, myocardial infarction, stent thrombosis, unplanned hospitalization for unstable angina, target lesion revascularization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction</measure>
    <time_frame>12 months</time_frame>
    <description>Incident rate of myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>12 months</time_frame>
    <description>Incident rate of stent thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization</measure>
    <time_frame>12 months</time_frame>
    <description>Incident rate of target lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unplanned hospitalization for unstable angina</measure>
    <time_frame>12 months</time_frame>
    <description>Incident rate of unplanned hospitalization for unstable angina</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural and in-hospital complications</measure>
    <time_frame>30 days</time_frame>
    <description>Incident rate of periprocedural myocardial infarction, bleedings and access site complication, failure to cross stent struts with guidewire in the treatment of bifurcation, failure to delivery the stent, contrast-induced nephropathy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding events</measure>
    <time_frame>12 months</time_frame>
    <description>Incident rate of bleedings classified according to the BARC criteria</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Coronary Artery Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients undergoing percutaneous treatment of coronary artery disease with
        implantation of a self-apposing, drug-eluting, Stentys stent
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 years old

          -  ability to provide informed consent

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudio Moretti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Cardiology, Department of Medical Sciences, AO Città della Salute e della Scienza, University of Turin, Turin, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Montefusco, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Cardiology, Department of Medical Sciences, AO Città della Salute e della Scienza, University of Turin, Turin, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernardo Cortese, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Interventional Cardiology, A.O. Fatebenefratelli Milano, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sebastiano Gili, MD</last_name>
    <phone>+393338354923</phone>
    <email>sebastiano.gili@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Antonio Montefusco, MD</last_name>
    <email>anto.montefusco@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Division of Cardiology, Mazzoni Hospital</name>
      <address>
        <city>Ascoli Piceno</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luciano Moretti, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Simona Silenzi, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Pierfrancesco Grossi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ferrarotto Hospital, University of Catania</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessio La Manna, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Division of Cardiology, ASL TO4</name>
      <address>
        <city>Cirie</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pietro Gaetano, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Division of Cardiology, Santa Maria dei Battuti Hospital</name>
      <address>
        <city>Conegliano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Pavei, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Division of Cardiology, Ospedale Civile di Legnano - ASST Ovest Mi</name>
      <address>
        <city>Legnano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnaldo Poli, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Interventional Cardiology, Azienda Ospedaliera Fatebenefratelli</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernardo Cortese, MD</last_name>
    </contact>
    <investigator>
      <last_name>Bernardo Cortese, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Division of Cardiology, Federico II University</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Esposito, MD, Prof</last_name>
    </contact>
    <contact_backup>
      <last_name>Plinio Cirillo, MD, Prof</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Division of Cardiology, Santa Corona Hospital</name>
      <address>
        <city>Pietra Ligure</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Maria Nicolino, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Division of Cardiology, Fondazione Toscana G Monasterio</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luigi Emilio Pastormerlo, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Cataldo Palmieri, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Division of Cardiology, Policlinico Umberto I, La Sapienza University</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gennaro Sardella, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Massimo Mancone, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Gennaro Sardella, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Massimo Mancone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simone Calcagno, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Division of Cardiology, ASST Bergamo Ovest</name>
      <address>
        <city>Treviglio</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Sganzerla, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AO Città della Salute e della Scienza</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastiano Gili, MD</last_name>
      <email>sebastiano.gili@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Antonio Montefusco, MD</last_name>
      <email>anto.montefusco@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Claudio Moretti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Montefusco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sebastiano Gili, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiology Department, Manipal Klang Hospital</name>
      <address>
        <city>Selangor</city>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kuan Leong Yew, MD, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Division of Cardiology, Medical University of Silesia</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grzegorz Smolka, MD, Prof</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Malaysia</country>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>Lu H, IJsselmuiden AJ, Grundeken MJ, Nassif M, de Vries AG, Weevers A, Scholte M, Spaargaren R, Wykrzykowska JJ, Tijssen JG, de Winter RJ, Koch KT. First-in-man evaluation of the novel balloon delivery system STENTYS Xposition S for the self-apposing coronary artery stent: impact on longitudinal geographic miss during stenting. EuroIntervention. 2016 Mar;11(12):1341-5. doi: 10.4244/EIJY15M05_07.</citation>
    <PMID>25983027</PMID>
  </reference>
  <reference>
    <citation>Pyxaras SA, Schmitz T, Naber CK. The STENTYS Self-Apposing® stent. EuroIntervention. 2015;11 Suppl V:V147-8. doi: 10.4244/EIJV11SVA34.</citation>
    <PMID>25983152</PMID>
  </reference>
  <reference>
    <citation>Farooq V, Gomez-Lara J, Brugaletta S, Gogas BD, Garcìa-Garcìa HM, Onuma Y, van Geuns RJ, Bartorelli A, Whitbourn R, Abizaid A, Serruys PW. Proximal and distal maximal luminal diameters as a guide to appropriate deployment of the ABSORB everolimus-eluting bioresorbable vascular scaffold: a sub-study of the ABSORB Cohort B and the on-going ABSORB EXTEND Single Arm Study. Catheter Cardiovasc Interv. 2012 May 1;79(6):880-8. doi: 10.1002/ccd.23177. Epub 2011 Oct 5.</citation>
    <PMID>22514149</PMID>
  </reference>
  <reference>
    <citation>Uren NG, Schwarzacher SP, Metz JA, Lee DP, Honda Y, Yeung AC, Fitzgerald PJ, Yock PG; POST Registry Investigators. Predictors and outcomes of stent thrombosis: an intravascular ultrasound registry. Eur Heart J. 2002 Jan;23(2):124-32.</citation>
    <PMID>11785994</PMID>
  </reference>
  <reference>
    <citation>Yew KL, Kang Z. First-in-man unprotected left main stenting with Stentys Xposition S self-apposing sirolimus eluting stent and optical coherence tomography guidance: The emerging panacea for left main intervention. Int J Cardiol. 2015 Dec 15;201:628-30. doi: 10.1016/j.ijcard.2015.08.035. Epub 2015 Aug 4.</citation>
    <PMID>26340130</PMID>
  </reference>
  <reference>
    <citation>Buccheri D, Orrego PS, Cortese B. Drug-eluting stent treatment of left main coronary artery disease: the case for a sirolimus-eluting, autoexpandable alternative. An optical coherence tomography analysis. Int J Cardiol. 2015 Nov 15;199:119-20. doi: 10.1016/j.ijcard.2015.07.006. Epub 2015 Jul 11.</citation>
    <PMID>26188831</PMID>
  </reference>
  <reference>
    <citation>van Geuns RJ, Yetgin T, La Manna A, Tamburino C, Souteyrand G, Motreff P, Koch KT, Vrolix M, IJsselmuiden A, Amoroso G, Berland J, Montalescot G, Teiger E, Christiansen EH, Spaargaren R, Wijns W. STENTYS Self-Apposing sirolimus-eluting stent in ST-segment elevation myocardial infarction: results from the randomised APPOSITION IV trial. EuroIntervention. 2016 Feb;11(11):e1267-74. doi: 10.4244/EIJV11I11A248.</citation>
    <PMID>26865444</PMID>
  </reference>
  <reference>
    <citation>Yew KL. Longitudinal stent foreshortening of Stentys Xposition S self-apposing stents and its impact on overlapping stenting strategy. Int J Cardiol. 2016 Feb 1;204:187-8. doi: 10.1016/j.ijcard.2015.11.176. Epub 2015 Nov 25.</citation>
    <PMID>26666346</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2016</study_first_submitted>
  <study_first_submitted_qc>May 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2016</study_first_posted>
  <last_update_submitted>December 16, 2016</last_update_submitted>
  <last_update_submitted_qc>December 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Città della Salute e della Scienza di Torino</investigator_affiliation>
    <investigator_full_name>Claudio Moretti</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>percutaneous coronary intervention</keyword>
  <keyword>stent implantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

